U.S. flag An official website of the United States government

On Oct. 1, 2024, the FDA began implementing a reorganization impacting many parts of the agency. We are in the process of updating FDA.gov content to reflect these changes.

U.S. Food and Drug Administration
  1. Home
  2. Vaccines, Blood & Biologics
  3. Blood & Blood Products
  4. Approved Blood Products
  5. ADYNOVATE
  1. Approved Blood Products

ADYNOVATE

STN: BL 125566
Proper Name: Antihemophilic Factor, Recombinant, PEGylated
Tradename: ADYNOVATE
Manufacturer: Takeda Pharmaceuticals U.S.A., Inc.
Indication:

Indicated in children and adults with hemophilia A (congenital factor VIII deficiency) for:

  • On-demand treatment and control of bleeding episodes
  • Perioperative management
  • Routine prophylaxis to reduce the frequency of bleeding episodes Limitation of Use

Product Information

Supporting Documents

 

Back to Top